Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Cediranib (Recentin™) – Profile of a novel anti-angiogenic agent in patients with malignant glioma

Dietrich J, D Wang, T Batchelor. Cediranib (Recentin™) – Profile of a novel anti-angiogenic agent in patients with malignant glioma. Expert Opinion on Investigational Drugs. 2009; 18(10):1-9.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.